Publication at Faculty of Medicine in Pilsen |
2016
Abstract
Alirocumab is a human monoclonal antibody against the enzyme proprotein convertase subtilisin/kexin type 9, which increases cholesterol clearance and reduces its blood concentration intensively about 50-60 % in average. It is also able to decrease secondary aims of lipid treatment (non-HDL cholesterol and apolipoprotein B).
Subcutaneously applied Alirocumab twice a month is very well tolerated and seems to be safe according to all clinical studies. Morbidity and mortality data concerning Alirocumab therapy and cardiovascular events are expected soon.